Investor Relations

HOME>Investor Relations

IR Calendar

2019

June 21: The 12th Ordinary General Meeting of Shareholders

May 10: Announcement of FY2018 Financial Results

February 4: Announcement of FY2018 3rd Quater Financial Results

IR Calendar list

What's New

2019

May 30		Withdrawal of Marketing Authorization Application of edaravone for ALS in the European Union
May 29		Launch of SIMPONI Subcutaneous Injection 50mg Autoinjector
May 24		Notice of Convocation of the 12th Ordinary General Meeting of Shareholders
May 16		IR Meeting for FY2018 Business Results[Transcript]
May 13		IR Meeting for FY2018 Business Results[Material][Video]
May 10		Announcement of Financial Results for FY2018 ⇒R&D Pipeline "State of New Product Development"
May 7		Analysts meeting on Revision to Consolidated Financial Forecasts for FY2018[Transcript]
April 26		Mitsubishi Tanabe Pharma and Salix enter into a licensing agreement for MT-1303, a therapeutic agent for autoimmune diseases
April 26		Medicago announced that its proprietary plant-based production platform, Proficia was awarded "Best New Vaccine Technology/Platform" at the World Vaccine Congress in Washington, D.C.
April 24		Analysts meeting on Revision to Consolidated Financial Forecasts for FY2018 [Material][Audio]
April 24		Revision to Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2019
April 15		For the ALS patients in the world, we hope to deliver Japan-originated ALS treatment―NMPA accepts our filing for Radicut to treat ALS in China
April 11		Notice Regarding Reorganization of Research, Production, and Technology Bases
March 28		The Global Health Innovative Technology Fund provides grant for joint research into anti-malarial drugs conducted by Mitsubishi Tanabe Pharma and a malaria research institution
March 20		Aiming to expand our sales and to strengthen our business foundations in the growing ASEAN market Establishment of sales subsidiary in Malaysia and Vietnam Representative Office
March 12		Topline Results of Japanese Phase 3 Clinical Studies of the HIF-PH Inhibitor MT-6548 in Anemia due to CKD
February 28		Tianjin Tanabe and Servier Tianjin join hands to promote TENELIA in China
February 20		Mitsubishi Tanabe Pharma Received Notice of Request for Arbitration
February 14		FDA accepted an Investigational New Drug Application for MT-8633, an ADC Targeting cMet Positive Solid Tumors
February 12		First Initiative in Digital Medicine Notice Regarding the Start of a Demonstration Project for TOMOCO, a Diabetes Care App
February 7		IR Meeting for FY2018 3rd Quarter Business Results[Transcript]
February 6		Swissmedic approves RADICAVA, Japan-originated ALS treatment
February 4		IR Meeting for FY2018 3rd Quarter Business Results[Material][Audio]
February 4		Announcement of FY2018 3rd Quarter Financial Results ⇒R&D Pipeline "State of New Product Development"
February 4		Notice Regarding Conclusion of Stock Transfer Agreement for Tanabe Seiyaku Yoshiki Factory Co., Ltd.